# ALPHA Sitagliptin Add on to Metformin (0431-103)

> **NCT00833027** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 608 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** sitagliptin phosphate

## Key facts

- **NCT ID:** NCT00833027
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-01
- **Primary completion:** 2009-10-30
- **Final completion:** 2009-10-30
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833027, "ALPHA Sitagliptin Add on to Metformin (0431-103)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00833027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*